Metabolic Profile and Anthropometric Changes in Schizophrenia (MetS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00534183 |
Recruitment Status :
Completed
First Posted : September 24, 2007
Last Update Posted : September 24, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metabolic Syndrome Diabetes Obesity | Drug: Olanzapine Drug: Risperidone Drug: Haloperidol | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2006 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Screening |
Official Title: | Metabolic Profile and Anthropometric Changes in Schizophrenia |
Study Start Date : | June 2006 |
Actual Study Completion Date : | December 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Olanzapine
|
Drug: Olanzapine
Olanzapine in dose range of 10-20mg |
Active Comparator: 2
Risperidone
|
Drug: Risperidone
Risperidone 1-6mg |
Active Comparator: 3
haloperidol
|
Drug: Haloperidol
Haloperidol 10-20mg |
- Study of metabolic profile [ Time Frame: 6 weeks ]
- Study of obesity and diabetes [ Time Frame: 6 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age between 18-40 years
- Diagnosis of schizophrenia
- Drug naive on admission
Exclusion Criteria:
- Other psychiatric co-morbidity
- History of severe physical illness
- Alcohol and substance abuse or dependence
- History of pre-existing diabetes or hypertension
- Family history of hypertension or diabetes

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00534183
India | |
Central Institute of Psychiatry | |
Ranchi, India, 834009 |
Principal Investigator: | Sahoo Saddichha, DPM | Central Institute of Psychiatry |
ClinicalTrials.gov Identifier: | NCT00534183 |
Other Study ID Numbers: |
CIPMETS001 |
First Posted: | September 24, 2007 Key Record Dates |
Last Update Posted: | September 24, 2007 |
Last Verified: | September 2007 |
Metabolic syndrome Obesity Diabetes |
Metabolic Syndrome Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Haloperidol Olanzapine Risperidone Haloperidol decanoate Serotonin Antagonists Serotonin Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators |